Evidence map›Paper›PMID 39479373›Full record

ArticleDigital health

Observational study of the Amaze™ asthma disease management platform.

Jehan Alladina, Peter P Moschovis, Hitesh N Gandhi, Donna Carstens, Elizabeth D Bacci, Katelyn Cutts, Karin S Coyne, Karen Goldsborough, Dawei Jiang, Conor O'Brien and 1 more

2 registry-linked trialsAbstract read
In one paragraph

Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04868500 nacompletednot on this map

Managing Asthma Patients With AMAZE™: A Novel Disease Management Platform, A Clinical Pilot Study

TypeinterventionalSponsorAstraZenecaRan2021 to 2021Enrolled49ConditionsAsthmaArmsAMAZE™ Application, AMAZE™ Dashboard
NCT04901260 completednot on this map

AMAZE™ Asthma Implementation Quality Improvement Study

TypeobservationalSponsorAstraZenecaRan2020 to 2021Enrolled117ConditionsAsthmaArmsAMAZE™ Disease Management Platform
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jehan AlladinaDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID https://orcid.org/0000-0003-0136-6859
Peter P MoschovisDivision of Pediatric Pulmonary Medicine, Massachusetts General Hospital, Boston, MA, USA.
Hitesh N GandhiBioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA.
Donna CarstensBioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA.
Elizabeth D BacciEvidera, Seattle, WA, USA.
Katelyn CuttsEvidera, Bethesda, MD, USA.
Karin S CoyneEvidera, Bethesda, MD, USA.
Karen GoldsboroughBioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA.
Dawei JiangMass General Brigham Hospital Integrated Research Organization, Boston, MA, USA.
Conor O'BrienMass General Brigham Hospital Integrated Research Organization, Boston, MA, USA.
T Bernard KinaneDivision of Pediatric Pulmonary Medicine, Massachusetts General Hospital, Boston, MA, USA.

Funding

Institutional Career Development CoreKL2TR002542 · NCATS · HARVARD MEDICAL SCHOOL · PI BREDELLA, MIRIAM ANTOINETTE, RUTKOVE, SEWARD B. · 2018 to 2022
$8.7M
The effect of household air pollution on lung function growth in infants with pneumonia in sub-Saharan Africa.K23ES030399 · NIEHS · MASSACHUSETTS GENERAL HOSPITAL · PI MOSCHOVIS, PETER P · 2019 to 2024
$1.1M
NCATS NIH HHS KL2 TR002542NIEHS NIH HHS K23 ES030399
6 · The paper itself

Abstract

Objective: Asthma is often inadequately controlled, which can result in exacerbations that lead to unplanned healthcare visits. Mobile application (app) use could help manage asthma exacerbations. We implemented the Amaze™ asthma disease management platform in clinical practice and assessed user satisfaction, usage, and usability. Methods: Adults with asthma and healthcare professionals (HCPs) were enrolled from a community allergy practice (ClinicalTrials.gov Identifier: NCT04901260) and a large academic hospital (ClinicalTrials.gov Identifier: NCT04868500). Primary and exploratory outcomes included assessment of platform design, patient app usage, patient-reported daily asthma status, emergency room/urgent care visits, and ease of implementation by HCPs. The system usability scale and a post-clinic visit survey were also administered. HCPs/staff monitored the Amaze dashboard to assess patient needs and completed a post-study survey. Results: Overall, 159 patients and five HCPs participated in the study. Patients' mean (SD) age was 38.7 (16.4) years; most were female (78%) and White (78%). Mean patient app usage began at 3.6 days/week but declined to 1.0 day/week by the end of the study. Throughout the study, most daily entries (>69%) reported patient asthma status as "good." Most patients were satisfied/very satisfied with the app (66%) and reported it helped them during discussions with their HCP (44%). Most patients rated the usability of Amaze as "excellent" (49%) or "good" (30%). Most HCPs (71%) reported that Amaze was "very easy" to implement. Conclusions: Most patients and HCPs were satisfied with Amaze. The Amaze platform may help patients and HCPs monitor asthma status, which could improve asthma control.

Indexed as

Asthma managementdigital technologymobile health

Identifiers

PMID39479373
PMCPMC11523167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.